Effects of Celecoxib After Percutaneous Coronary Intervention

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography

Exclusion Criteria:

• Acute ST elevation MI

• Left main disease

• Contraindications to aspirin, clopidogrel or celecoxib

• Severe congestive heart failure

• Expected survival < 2 years

• Hepatic dysfunction

• Currently taking NSAIDs or any COX-2 inhibitor

• Renal dysfunction

• Use of warfarin